Showing 8,701 - 8,720 results of 11,885 for search '(( significant ((level decrease) OR (teer decrease)) ) OR ( significant we decrease ))', query time: 0.61s Refine Results
  1. 8701
  2. 8702

    Supplementary file 1_Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF splicing in pituitary somatotroph tumoral cells.jpeg by Donatella Treppiedi (10146335)

    Published 2025
    “…Moreover, SRPIN340 significantly decreased both transcript (-56.3 (38.6)%, p<0.01 vs control cells) and protein levels (-33.5 (3.4)%, p<0.05 vs control cells) of the pro-survival VEGF164a isoform. …”
  3. 8703

    Image 1_Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF splicing in pituitary somatotroph tumoral cells.jpg by Donatella Treppiedi (10146335)

    Published 2025
    “…Moreover, SRPIN340 significantly decreased both transcript (-56.3 (38.6)%, p<0.01 vs control cells) and protein levels (-33.5 (3.4)%, p<0.05 vs control cells) of the pro-survival VEGF164a isoform. …”
  4. 8704

    Disturbances in drylands: Interactions among herbivory, drought, and termite activity in savanna plant communities by Harry Wells (11430190)

    Published 2025
    “…The impacts of these events may be modulated by biotic agents in unpredictable ways, yet few experiments cover sufficient spatiotemporal scales to measure the interactive effects of multiple extreme events. We used 15 years of a 28-year experiment spanning several significant droughts to investigate how rainfall, large herbivores, and soil-engineering termites affect understory vegetation in a semi-arid savanna. …”
  5. 8705

    Multi-Omics Insights into Microbiome and Metabolite Signatures as Potential Biomarkers for Feline Hypertrophic Cardiomyopathy by Yuhong Wu (21545486)

    Published 2025
    “…Correlation analysis showed <i>Blautia</i> was associated with serum norepinephrine levels; <i>Helicobacter</i> showed a significant positive correlation with acylcarnitines and amino acid metabolites; <i>Helicobacter</i> and <i>Romboutsia</i> were significantly negatively correlated with phospholipid metabolites. …”
  6. 8706

    Table 2_Downsizing chronic disease management programs for type 2 diabetes patients during the COVID-19 pandemic: changes in healthcare utilization patterns.docx by Corinne Rijpkema (12587274)

    Published 2025
    “…In Q1 of 2020, type 2 diabetes patient visits to out-of-hours GP services rose notably, but decreased in Q1 of 2021, compared to 2019. Hospital care for diabetes showed a significant increase in Q2 of 2021 (+11.3%), compared to Q2 2019 and regular GP care increased from Q1 2021 (up to +11.1% in Q3 2021). …”
  7. 8707

    Image 2_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.jpeg by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  8. 8708

    Table 1_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  9. 8709

    Image 1_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.jpeg by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  10. 8710

    Table 7_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  11. 8711

    Table 6_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  12. 8712

    Table 2_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  13. 8713

    Table 1_Downsizing chronic disease management programs for type 2 diabetes patients during the COVID-19 pandemic: changes in healthcare utilization patterns.docx by Corinne Rijpkema (12587274)

    Published 2025
    “…In Q1 of 2020, type 2 diabetes patient visits to out-of-hours GP services rose notably, but decreased in Q1 of 2021, compared to 2019. Hospital care for diabetes showed a significant increase in Q2 of 2021 (+11.3%), compared to Q2 2019 and regular GP care increased from Q1 2021 (up to +11.1% in Q3 2021). …”
  14. 8714

    Data Sheet 1_Plausibility of super high-flux dialyzer reuse in maintenance hemodialysis.pdf by Piyapun Prapunwatana (22474063)

    Published 2025
    “…Dialysate albumin loss decreased significantly from 1.01 g during the 1st use to 0.19 g during the 2nd and 0.06 g during the 5th use (p-value < 0.001). …”
  15. 8715

    Data Sheet 1_Extracorporeal photopheresis as induction therapy in lung transplantation for cystic fibrosis: a pilot randomized trial.docx by Ilaria Righi (10198817)

    Published 2025
    “…Exploratory endpoint analyses revealed significant decreases in pro-inflammatory cytokines, degranulating CD8<sup>+</sup> T lymphocytes, and NK cells in the treatment group. …”
  16. 8716

    Table 4_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  17. 8717

    Table 3_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  18. 8718

    Data Sheet 1_Long-term effects of SGLT2 inhibitors on arrhythmias: a systematic review and meta-analysis.pdf by Peipei Li (552532)

    Published 2025
    “…The results of meta-analysis revealed that patients treated with SGLT2 inhibitors had a reduced risk of AF/AFL compared with placebo (RR 0.86; 95%CI, 0.77–0.95; I<sup>2</sup> = 0%; P = 0.003). There was no significant difference in the risk of AF/AFL between the high-dose SGLT2 inhibitors group and the low-dose SGLT2 inhibitors group (RR 0.78; 95%CI, 0.60–1.02; I<sup>2</sup> = 0%; P = 0.07), although a decreasing trend in the high-dose group was noted. …”
  19. 8719

    Table 5_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  20. 8720

    Table 1_Experiences of childhood emotional maltreatment and emotional intelligence in young women.docx by Thomas Suslow (315131)

    Published 2025
    “…Regression analysis indicated that emotional neglect was a significant predictor of understanding emotion independent of women’s verbal intelligence, cognitive flexibility, trait anxiety, and depressive symptoms. …”